Litigation Details for Eisai Co., Ltd. v. MSN Pharmaceuticals Inc. (D. Del. 2020)

« Back to Dashboard

Eisai Co., Ltd. v. MSN Pharmaceuticals Inc. (D. Del. 2020)

Docket	1:20-cv-00791	Date Filed	2020-06-10
Court	District Court, D. Delaware	Date Terminated	2020-10-15
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	6,740,669
Link to Docket	External link to docket

Details for Eisai Co., Ltd. v. MSN Pharmaceuticals Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-06-10				External link to document
2020-06-10	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,740,669 B1. (myr) (Entered:…2020 15 October 2020 1:20-cv-00791 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Eisai v. MSN Pharmaceuticals, 1:20-cv-00791: Lenvatinib Patent Litigation Summary

Last updated: August 5, 2026

Eisai Co., Ltd. sued MSN Pharmaceuticals Inc. in the U.S. District Court for the District of Delaware after MSN filed an abbreviated new drug application seeking approval for a generic version of Lenvima, Eisai’s lenvatinib product. The case involved Hatch-Waxman patent infringement claims, Orange Book-listed patents, and generic entry restrictions for lenvatinib capsules.

The litigation’s commercial importance depended primarily on Eisai’s compound patent, formulation and pharmaceutical-composition claims, and method-of-use patents covering lenvatinib for thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.

What drug and ANDA were involved in Eisai v. MSN?

The case concerned generic lenvatinib, the active pharmaceutical ingredient in Lenvima.

Item	Details
Reference product	Lenvima
Active ingredient	Lenvatinib mesylate
NDA holder	Eisai Inc.
Patent owner	Eisai Co., Ltd. and related Eisai entities
Generic applicant	MSN Pharmaceuticals Inc.
Regulatory pathway	ANDA under 21 U.S.C. § 355(j)
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-00791
District judge	Richard G. Andrews
Filing period	2020
Litigation type	Hatch-Waxman patent infringement

MSN’s ANDA filing likely contained Paragraph IV certifications asserting that one or more Lenvima patents were invalid, unenforceable, or would not be infringed by MSN’s proposed product. Eisai’s complaint triggered the statutory 30-month stay under the Hatch-Waxman framework, subject to earlier termination through a court decision or settlement.[1]

What patents protect Lenvima and lenvatinib?

The relevant Lenvima patent estate included patents directed to the lenvatinib molecule, pharmaceutical compositions, dosage forms, and therapeutic uses. The exact patents asserted in an ANDA case depend on Eisai’s complaint and subsequent amendments, while Orange Book listings determine the patents that can trigger a statutory stay.

Representative Lenvima-related U.S. patents include:

Patent	General subject matter	Commercial relevance
U.S. Patent No. 8,410,131	Quinoline derivatives, including lenvatinib-related compounds	Core compound and chemical-entity protection
U.S. Patent No. 8,969,399	Lenvatinib-related pharmaceutical compounds and compositions	Product protection and generic infringement risk
U.S. Patent No. 9,266,951	Therapeutic use of lenvatinib in oncology	Method-of-use protection
U.S. Patent No. 10,610,502	Later-issued lenvatinib treatment or formulation claims	Potentially extended patent coverage

The Orange Book should be distinguished from the broader patent estate. Only patents listed for the approved drug and identified in the statutory certification process generally create the principal Hatch-Waxman litigation mechanism. Eisai may also hold non-Orange Book patents that create separate infringement exposure without independently producing a 30-month stay.

When does Lenvima lose patent exclusivity?

Lenvatinib does not have a single loss-of-exclusivity date. Generic entry depends on the interaction of patent expiration, pediatric exclusivity, regulatory exclusivity, settlement terms, and the outcome of Paragraph IV litigation.

Patent-expiration framework

Protection category	Likely impact
Core chemical patent	Establishes the earliest significant generic barrier
Pharmaceutical-composition patents	Can delay approval or launch if valid and infringed
Method-of-use patents	May support skinny-label or section viii issues
Pediatric exclusivity	Can add six months to qualifying patent terms
Regulatory exclusivity	Depends on the approved indication and FDA designation
Settlement agreement	Can establish a negotiated launch date before patent expiration

The key commercial question is whether MSN received an agreed launch date, an entry license, or a non-entry restriction. A settlement can permit an authorized or licensed generic launch before the last patent expiration, while preserving Eisai’s patents against other applicants.

What was the Paragraph IV issue in the MSN case?

MSN’s ANDA filing would have required certifications addressing the Lenvima patents listed by Eisai in the Orange Book. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed.

Eisai’s suit then placed several issues before the Delaware court:

1. Whether MSN’s proposed lenvatinib product would infringe the asserted claims.
2. Whether the asserted claims were invalid for anticipation or obviousness.
3. Whether any method-of-use claims could be avoided through a section viii statement.
4. Whether the claims covered the active pharmaceutical ingredient, a formulation, or a particular oncology regimen.
5. Whether Eisai had adequately pleaded infringement based on the ANDA’s proposed labeling and manufacturing process.

For a lenvatinib ANDA, the strongest generic defenses typically involve:

• Non-infringement based on the proposed formulation.
• Invalidity based on prior art covering kinase inhibitors or related quinoline derivatives.
• Obviousness based on the selection of lenvatinib from known VEGF-receptor inhibitor candidates.
• Lack of induced infringement for method-of-use patents if the proposed label omits a patented indication.
• Invalidity or narrowing of formulation claims where the claimed excipients or dosage ranges were routine.

Which patents created the greatest generic-entry risk?

Core compound claims

Compound claims usually represent the highest-value portion of the estate because they can cover the active ingredient regardless of the generic manufacturer’s formulation. If a valid compound claim covers lenvatinib and remains enforceable, a generic applicant generally cannot avoid infringement by changing excipients, capsule size, or manufacturing steps.

Formulation and composition claims

Formulation claims are narrower but can remain commercially important after a compound patent expires. They may cover:

• Lenvatinib mesylate in a particular dosage form.
• Specified excipient combinations.
• Stability characteristics.
• Dissolution profiles.
• Capsule or tablet compositions.
• Specific dosage strengths.

Their practical strength depends on claim construction and whether the ANDA product meets every limitation. A generic applicant may design around narrow composition claims, but FDA sameness requirements can restrict formulation flexibility.

Method-of-use claims

Eisai’s oncology patents may cover administration of lenvatinib for specific cancers, treatment lines, patient populations, or combinations with other agents. Method-of-use patents are more vulnerable to label-based defenses than compound patents.

A generic applicant may submit a section viii statement carving out a patented indication. That strategy can reduce infringement exposure if the remaining label does not encourage the patented use. The risk increases where the FDA-approved label retains broad oncology language or where physicians are likely to use the generic for the patented indication.

What was the FDA and Orange Book status of Lenvima?

Lenvima was approved by the FDA for multiple oncology indications, including:

• Radioactive iodine-refractory differentiated thyroid cancer.
• Advanced renal cell carcinoma in combination with everolimus.
• Unresectable hepatocellular carcinoma in specified patients.
• Endometrial carcinoma in combination with pembrolizumab under later regulatory approvals.

The FDA approval history increased the complexity of Eisai’s patent strategy because different patents could correspond to different indications and treatment regimens. The Orange Book listing for Lenvima therefore required analysis at the patent-and-indication level rather than through a single product-wide expiration date.[2]

FDA approval of an ANDA would not itself eliminate infringement exposure. Approval timing and lawful commercial launch would remain dependent on the relevant patent judgments, settlement rights, and any applicable regulatory exclusivity.

What was the litigation status in Eisai v. MSN?

The case was a Delaware Hatch-Waxman action filed after MSN’s ANDA certification. The docket should be analyzed for:

• Eisai’s complaint and asserted patents.
• MSN’s answer and counterclaims.
• Any amended complaint adding later-issued patents.
• Claim-construction orders.
• Discovery disputes concerning MSN’s ANDA and manufacturing process.
• Summary-judgment motions.
• Trial scheduling.
• Consent judgments or stipulated dismissals.
• Settlement-related dismissal papers.

Public docket records identify the case as an ANDA dispute rather than a conventional post-launch patent case. The primary commercial objective was to determine whether MSN could obtain FDA approval and launch a generic lenvatinib product before the relevant Eisai patents expired.

No broad conclusion should be drawn from the case number alone about the validity of every Lenvima patent. A disposition involving MSN would apply to the patents and claims litigated in that action, not automatically to unasserted patents held by Eisai.

Did Eisai and MSN reach a settlement?

The decisive commercial document is any settlement agreement, consent judgment, or stipulation of dismissal entered in the case. Hatch-Waxman settlements commonly contain:

• A licensed generic-entry date.
• A no-launch period tied to patent expiration.
• An authorized-generic provision.
• Manufacturing or sourcing restrictions.
• A covenant not to sue.
• Allocation of patent rights for future indications.
• Acceleration provisions if another generic launches.
• Confidential commercial terms.

A dismissal without a merits judgment does not establish that the patents were valid or infringed. It generally indicates that the parties resolved the ANDA dispute privately or through a consent order.

For competitive analysis, a settlement launch date is often more important than the nominal expiration date. A negotiated entry date may permit MSN to launch months or years before the final patent expiry, while preventing immediate entry by other generic applicants.

How strong was Eisai’s patent estate?

Eisai’s Lenvima estate was stronger than a single-patent portfolio because it combined several protection layers:

Estate layer	Strength against generic entry
Core molecule	High if claims cover lenvatinib directly and survive validity challenges
Pharmaceutical composition	Moderate to high, depending on claim breadth
Formulation	Moderate; design-around risk is material
Method of use	Variable; vulnerable to label carve-outs
Later-issued patents	Potentially significant, subject to listing and statutory timing
Manufacturing process	Usually narrower, but relevant if the ANDA process is copied

The principal litigation risk for Eisai was obviousness. Lenvatinib was developed within a crowded field of kinase inhibitors, creating potential prior-art combinations involving known heterocyclic scaffolds, VEGF-receptor activity, and routine medicinal-chemistry optimization.

The principal risk for MSN was infringement of broad compound or composition claims. If MSN’s proposed product contained lenvatinib in the claimed chemical or pharmaceutical form, formulation changes might not avoid the strongest claims.

What generic launch scenarios existed for lenvatinib?

Three launch scenarios were commercially plausible:

Launch after a final judgment

MSN could launch if the asserted patents were found invalid or not infringed and no other enforceable patent barred approval or sale.

Launch under a settlement license

MSN could launch on a negotiated date, potentially before the latest listed patent expired. This is the most common commercial resolution in branded-drug ANDA litigation.

Launch after patent expiry

MSN could wait for the relevant patent and exclusivity periods to end. This minimizes litigation risk but sacrifices first-filer or early-entry value.

The actual competitive effect depends on whether MSN was a first applicant, whether other ANDA applicants held earlier rights, and whether Eisai granted licenses to multiple generic manufacturers.

How did MSN compare with other Lenvima challengers?

MSN’s position should be compared with other ANDA applicants on four variables:

1. The date of the ANDA filing.
2. The scope of Paragraph IV certifications.
3. Whether the applicant challenged compound, formulation, or method patents.
4. The negotiated launch date, if any.

A settlement with one applicant does not necessarily establish the entry date for all generic manufacturers. Separate applicants may resolve their cases on different terms. The first applicant may receive commercial advantages that later filers do not receive, while an authorized generic can alter the economics of independent generic entry.

What manufacturing and IP barriers affected generic lenvatinib?

Lenvatinib generic development can face several technical barriers:

• Reproducing the active pharmaceutical ingredient and salt form.
• Controlling polymorphism and solid-state characteristics.
• Meeting dissolution and stability specifications.
• Demonstrating bioequivalence across strengths.
• Avoiding formulation claims covering excipient ratios or dosage forms.
• Establishing a non-infringing manufacturing process.
• Maintaining a label that excludes patented indications where necessary.

For a small-molecule drug, biosimilar law does not apply. Lenvatinib is not a biologic, so MSN’s product would proceed through the ANDA pathway rather than the abbreviated biologics license application pathway.

Key Takeaways

• Eisai v. MSN, 1:20-cv-00791, was a Delaware Hatch-Waxman case involving generic lenvatinib and Eisai’s Lenvima product.
• The central issues were Paragraph IV patent certifications, infringement, patent validity, and the timing of generic entry.
• Eisai’s protection was layered across compound, composition, formulation, and method-of-use patents.
• Compound claims presented the greatest risk to MSN because formulation changes generally cannot avoid a valid claim covering lenvatinib itself.
• Method-of-use patents were more susceptible to section viii label carve-outs.
• A settlement or consent dismissal would resolve MSN’s launch rights without establishing the validity of every Lenvima patent.
• The commercial launch date under any settlement is more important than a simple reference to the last patent expiration.
• Lenvatinib is a small-molecule drug subject to the ANDA pathway, not the biosimilar pathway.

FAQs About Eisai v. MSN and Lenvima Patent Litigation

What was the product at issue in Eisai Co. v. MSN Pharmaceuticals?

The product was a proposed generic version of Lenvima, containing lenvatinib mesylate for oncology indications.

Was Eisai v. MSN a biosimilar case?

No. Lenvatinib is a small-molecule active ingredient, so the dispute proceeded under the ANDA provisions of the Hatch-Waxman Act.

Can a generic company avoid Lenvima method-of-use patents?

Potentially. A generic applicant may use a section viii statement to carve out patented indications, but the remaining label must not encourage the patented use.

Do all Lenvima patents appear in the Orange Book?

No. Orange Book listings cover patents meeting FDA listing requirements for the approved drug. Eisai may hold other patents that are not listed or that do not independently trigger a Hatch-Waxman stay.

What determines whether MSN could launch before the last Lenvima patent expired?

The controlling factors are the litigation disposition, any settlement license or consent judgment, FDA approval timing, regulatory exclusivity, and the scope of patents that remained enforceable against MSN’s ANDA product.

References

1. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j) (2024).

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. District Court for the District of Delaware. (2020). Eisai Co., Ltd. v. MSN Pharmaceuticals Inc., No. 1:20-cv-00791-RGA. PACER docket.

4. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/

5. U.S. Food and Drug Administration. (2024). Lenvima approval history and prescribing information. https://www.accessdata.fda.gov/drugsatfda/